Table 1 |.
Summary of humanized mouse models
| Model | Mouse strain | Human tissue | Application | Investigator |
|---|---|---|---|---|
| Humanized mouse models without fetal tissue | ||||
| Neo Thy humanized mouse | NSG NBSGW |
Cryopreserved neonatal thymus Umbilical cord blood |
Immunogenicity studies | M. Brown |
| NRG-Akita | NOD-Rag1nullIl2rgnullIns2Akita | Juvenile human islets; umbilical cord blood | Islet allotransplantation | M. Brehm |
| NSG-Hu-PBL | NSG | PBMCs | HIV/AIDS (long-acting drugs); gene therapy; visualizing HIV-1 infection | P. Kumar |
| NSG-HSC | NSG | Umbilical cord blood | Arboviruses (flavivirus, alphavirus and bunyaviruses) | R. Rico-Hesse |
| NSG | Umbilical cord blood | Analysis of immunological perturbations (autoimmunity) | K.C. Herald | |
| Testing of long-acting anti-HIV therapies | L. Poluektova | |||
| NOG-hlL34 | Umbilical cord blood | Infection of human microglia with HIV | L. Poluektova | |
| NSG or NRG HIS mice | NSG, NRG | Umbilical cord blood | Study of B cell development and pediatric bacterial vaccines | T. Manser |
| Mouse viral outgrowth assay | NSG | PBMCs from HIV-infected patients | Detection of replication-competent HIV | R. Akkina |
| NOD SCID | NOD SCID B2m−/− | Adult CD34+ HSCs | Adoptive T cell transfer | K. Palucka |
| BRGS-hu | BRGS | Umbilical cord blood | Development of colorectal cancer PDX hu mice; EBV type 2 infection; B cell lymphomagenesis | R. Pelanda |
| MISTRG | Immunodeficient Rag2−/− ll2rg−/− mice with human M-CSF, IL-3, GM-CSF, TPOandSIRPα | Umbilical cord blood | Efficient development of myeloid cells and NK cells | A.Rongvaux |
| Humanized mouse models with fetal tissue | ||||
| BLT | NSG | Fetal liver and thymus | HIV/AIDS | T. Allen |
| Zika virus | R. Akkina | |||
| Comparison of biologies; cytokine-release syndrome; checkpoint inhibitor adverse events | K. Howard | |||
| Vaccine and NK cell studies | S. Paust | |||
| TKO-BLT | TKO | Fetal liver and thymus | HIV–AIDS | K. Hasenkrug |
| NSG-SGM3-BLT | NSG-SGM3 | Fetal liver and thymus | Development of human mast cells for anaphylaxis studies; human macrophage-mediated fibrosis in would healing | M. Brehm |
| NSG-HSC | NSG | HSCs from fetal liver | Mouse skin transplant model; type 1 diabetes; aberrant immune responses; microbiota control | K.C. Herald |
| NSG or NRG HIS mice | NSG, NRG | HSCs from fetal liver | Study of B cell development and pediatric bacterial vaccines | T. Manser |
| SCID-huThy/Liv | C.B-17scid | Fetal liver and thymus | Isolation of candidate human stem cell populations and CNS stem cells; growth of cancer stem cells in mice; HIV–AIDS | Weissman I |
| AFC-hu HSC/Hep | AFC8/BRG | Hepatocytes and HSCs from fetal liver | Human liver fibrosis after HCV infection | L. Su |
| A2/NSG-hu HSC/Hep | A2/NSG | Hepatocytes and HSCs from fetal liver | Human liver fibrosis after HBV infection | L.Su |
| Human microglia mouse | NOG-hlL34 | Fetal brain and liver tissue | Study of neurotropic infections, such as infection with HIV, CMV, Zika virus, JCPyV | L. Poluektova |
| Fetal human thymus mouse model | NSG | Fetal human thymus plus CD34+ cells | Study of T cell homeostasis, Treg cell development, human T cell repertoire development, transplantation tolerance, in vivo analysis of human immune responsiveness | M. Sykes |
| UCLA service core | BLT, SCID-hu, hu-PBL SCID, NOG-hu, BLT-NOD.SCID, HIS-DKO, NRG-BLT | Fetal liver and thymus | IND-enabling studies in HIV–AIDS, oncology, hematopoietic disorders, gene therapy, immunotherapy, and infectious disease | S. Kitchen |
NBSGW, NOD.Cg-KitW−41JTyr + PrkdcscidIl2rgtm1Wjl/ThomJ; TKO, B6.129S-Rag2tm1FwaCd47tm1FplIl2rgtm1Wjl/J; NRG, NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ; BRGS, BALB/c Rag2tm1FwaIl2rgtm1CgnSirpaNOD; MISTRG, C;129S4-Rag2tm1.1FlvCsf1tm1(CSF1)FlvCsf2/Il3tm1.1(CSF2,IL3)FlvThpotm1.1(TPO)FlvIl2rgtm1.1FlvTg(SIRPA)1Flv/J; B2m, gene encoding β2-microglobulin; EBV, Epstein-Barr virus; CMV, cytomegalovirus; CNS, central nervous system; JCPyV, JC polyomavirus; KO, knockout; PDX, patient-derived xenograft; NK, natural killer; Treg cell, regulatory T cell; IND, investigational new drug.